Eli Lilly’s shares crashed in the early trading on Tuesday after it released its forecast for revenue between 2024-2025.
Shares of the pharma giant fell by around 8% after it cut its revenue forecast for this year.
Stocks have dropped by over 22 percent in six months.
Eli Lily revenue forecast for 2024
Eli Lilly expects worldwide revenues of around $45.0 billion for 2024. This represents a growth of 32% over the previous year, but is still slightly lower than consensus estimates of $45.49billion.
In October, the company shared its revenue forecast of $45.4 to $46 Billion.
The company anticipates revenue in the fourth quarter of 2024 of about $13.5 billion. This is a growth of 45% over last year, but still below consensus at $13.97 billion.
The revised Q4 revenue guidance for 2024 is about $400 million or 3% lower than what was provided in the earnings call of the third quarter.
This is attributed to the fact that incretin growth in the U.S. market has been slower than expected and channel inventories at year’s end were lower than anticipated.
Mounjaro, with $3.5 billion in revenue, and Zepbound ($1.9 billion) are the two main contributors.
The non-incretin revenues also grew strongly, by 20 percent year-over-year. This was largely due to the oncology and immunology medicines, as well as neuroscience drugs.
David Ricks Lilly Chairman and CEO highlighted the ongoing efforts of Lilly to improve manufacturing capabilities.
We’ll add additional production capacity and we expect at least 60% higher sales of incretins during the first six months of this year than in the first six months of 2024.
Ricks also highlighted the performance of medicines that do not contain incretins and progress made by manufacturers to keep up with demand.
Eli Lily revenue forecast 2025
Eli Lilly’s revenue projections for 2025 are in a range between $58.0 and $61.0 billion. This is higher than the $58.6 consensus estimate. This outlook is a reflection of the company’s optimism regarding its portfolio and growth strategy.
The strong performance of the new drugs such as Jaypirca and Ebglyss is a key driver of this growth.
The company expects these treatments to be a big hit in the next year and contribute significantly to its bottom line.
Mounjaro’s expansion into new markets will also boost revenue.
This therapy is poised for further growth and will continue to be a major contributor.
Eli Lilly also looks forward to the potential launch of new treatments, such as imlunestrant, which is a promising treatment for metastatic breast carcinoma. These additions, if approved, could strengthen the position of the company in the pharmaceutical sector.
In addition to market trends and inventory levels, the company also considers in its 2025 forecasts changes in channel inventories as well as incretins’ dynamics.
Eli Lilly is confident about its future growth, and attributes this to the strong demand of existing products as well as a pipeline full of promising new treatments.
On February 6, 2025, the company plans to release its complete Q4 financial results for 2024, as well as its 2025 financial forecast, which includes other metrics that are included in their financial guidance.
As updates occur, this post Eli Lily reduces 2024 revenue forecast by $400M and shares fall 8% could be updated.
This site is for entertainment only. Click here to read more
